

Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.

| | |
|------------------------------|---|
| 著者 | TAGA Takashi, Tanaka Shiro, HASEGAWA Daisuke, TERUI Kiminori, TOKI Tsutomu, IWAMOTO Shotaro, HIRAMATSU Hidefumi, MIYAMURA Takako, HASHII Yoshiko, MORITAKE Hiroshi, NAKAYAMA Hideki, TAKAHASHI Hiroyuki, SHIMADA Akira, TAKI Tomohiko, ITO Etsuro, HAMA Asahito, ITO Masafumi, KOH Katsuyoshi, HASEGAWA Daiichiro, SAITO Akiko M., ADACHI Souichi, TOMIZAWA Daisuke |
| journal or publication title | Leukemia |
| year | 2021-09-01 |
| URL | http://hdl.handle.net/10422/00013077 |

doi: 10.1038/s41375-021-01397-w(<https://doi.org/10.1038/s41375-021-01397-w>)

AUTHOR CORRECTION



Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome

Takashi Taga , Shiro Tanaka, Daisuke Hasegawa , Kiminori Terui, Tsutomu Toki , Shotaro Iwamoto , Hidefumi Hiramatsu , Takako Miyamura , Yoshiko Hashii, Hiroshi Moritake , Hideki Nakayama , Hiroyuki Takahashi , Akira Shimada, Tomohiko Taki, Etsuro Ito , Asahito Hama , Masafumi Ito, Katsuyoshi Koh , Daiichiro Hasegawa, Akiko M. Saito, Souichi Adachi and Daisuke Tomizawa

© The Author(s), under exclusive licence to Springer Nature Limited 2021

Correction to: *Leukemia* <https://doi.org/10.1038/s41375-021-01157-w>, published online 15 February 2021

Following the publication of this article, the authors noted an error in the data reported.

One patient in the AML-D11 study (showing negativity for both FCM-MRD and GATA1-MRD) was incorrectly reported dead after relapse following a data input error. After re-confirming the survival data for all other patients, the dataset has been updated and results are as follows.

- The number of patients who relapsed was decreased from 7 to 6.
- The 3-year event-free survival (EFS) and overall survival (OS) rates in the entire population ($n = 78$) were 88.5 and 91.0%.
- The 3-year EFS and OS rates in the SR patients ($n = 76$) were 90.8 and 93.4%.
- The 3-year EFS and OS rates were 95.0 and 96.7% in the FCM-MRD-negative population, and 60.0 and 80.0% in the positive population.

- Three-year EFS and OS rates were both 98.1% in the GATA1-MRD-negative population, and 57.1 and 71.4% in the positive population.
- The adjusted hazard ratios for the association of FCM-MRD with EFS and OS were 14.67 (95% CI, 2.00–107.79; $p = 0.01$) and 13.48 (0.81–224.27; $p = 0.07$), respectively, while multivariate analysis of GATA1-MRD did not converge in the updated dataset due to the limited number of events in the GATA1-MRD-negative population.

Table 2, Supplementary Table 4, and Figs. 3 and 4 have been corrected and are shown below.

The conclusions of the article remain unchanged.

Table 2. Multivariate Cox regression of FCM-MRD for event-free and overall survivals in the standard risk population.

| | EFS | | | OS | | |
|--|-------|-------------|----------|-------|-------------|----------|
| | HR | 95% CI | <i>p</i> | HR | 95% CI | <i>p</i> |
| Analysis of FCM-MRD ($N = 65$, including five MRD-positive patients) | | | | | | |
| MRD at Time point 2 | | | | | | |
| Negative | Ref | | | Ref | | |
| Positive | 14.67 | 2.00–107.79 | 0.01 | 13.48 | 0.81–224.27 | 0.07 |
| Cytogenetics | | | | | | |
| Other abnormalities | Ref | | | Ref | | |
| 1q loss | 6.03 | 0.53–69.21 | 0.15 | 10.68 | 0.67–170.88 | 0.09 |
| Platelet (per $10^{10}/L$ increase) | 1.09 | 0.87–1.37 | 0.45 | 0.95 | 0.65–1.37 | 0.77 |

MRD minimal residual disease, EFS event-free survival, OS overall survival, HR hazard ratio, CI confidence interval.

Multivariate analysis of GATA1-MRD did not converge due to the limited number of events in the GATA1-MRD-negative population.

Table S4. Univariate Cox regression of prognostic factors for event-free and overall survivals among 78 patients.

| | EFS | | | OS | | |
|---|---------------|-------------|------|---------------|------------|------|
| | HR | 95% CI | p | HR | 95% CI | P |
| Age at diagnosis \geq 24 months | 4.71 | 1.05–21.07 | 0.04 | 5.28 | 0.88–31.61 | 0.07 |
| Girl | 0.81 | 0.18–3.64 | 0.79 | 1.71 | 0.29–10.22 | 0.56 |
| Mosaic 21 trisomy | 3.56 | 0.65–19.42 | 0.14 | 7.32 | 1.03–52.05 | 0.05 |
| History of TAM | 0.52 | 0.12–2.31 | 0.39 | 0.45 | 0.08–2.72 | 0.39 |
| Cardiac complication | 0.71 | 0.13–3.90 | 0.70 | 0.36 | 0.05–2.55 | 0.31 |
| FAB classification | | | | | | |
| M1 | 18.24 | 2.04–163.20 | 0.01 | Not estimable | | |
| M7 | 1.68 | 0.38–7.49 | 0.50 | 3.51 | 0.59–20.99 | 0.17 |
| RAEB-T | 1.28 | 0.25–6.57 | 0.77 | 2.10 | 0.35–12.60 | 0.41 |
| RAEB | 0.23 | 0.03–1.95 | 0.18 | Not estimable | | |
| RA | Not estimable | | | Not estimable | | |
| White blood cells (per $10^6/L$ increase) | 1.00 | 1.00–1.00 | 0.38 | 1.00 | 1.00–1.00 | 0.55 |
| Hemoglobin (per 1-g/dL increase) | 0.81 | 0.61–1.08 | 0.16 | 0.86 | 0.61–1.21 | 0.39 |
| Platelet (per $10^{10}/L$ increase) | 1.08 | 0.92–1.27 | 0.36 | 1.04 | 0.85–1.28 | 0.68 |
| Cytogenetics | | | | | | |
| Normal karyotype | 0.54 | 0.06–4.60 | 0.57 | Not estimable | | |
| Monosomy 7 | Not estimable | | | Not estimable | | |
| Monosomy 7 (complex) | 1.92 | 0.22–16.47 | 0.55 | 3.59 | 0.37–34.55 | 0.27 |
| Sole trisomy 8 | Not estimable | | | Not estimable | | |
| Complex | 1.78 | 0.21–15.23 | 0.60 | 2.83 | 0.29–27.23 | 0.37 |
| 1q loss | 6.11 | 1.12–33.39 | 0.04 | 12.41 | 1.75–88.28 | 0.01 |
| 7p loss | 1.35 | 0.16–11.60 | 0.78 | 2.18 | 0.23–20.97 | 0.50 |
| Acquired +21 | Not estimable | | | Not estimable | | |
| Others | 1.44 | 0.29–7.15 | 0.65 | 1.41 | 0.20–10.01 | 0.73 |
| GATA1 mutation | 7.03 | 0.84–58.88 | 0.07 | Not estimable | | |

EFS event-free survival, OS overall survival, HR hazard ratio, CI confidence interval.

